Abstract
Generalized seizures during Interferon-alpha (IFN-α) therapy have been repeatedly described in about 1%–4% of patients. However, the mechanisms underlying IFN-α induced seizures are not known. We describe a patient who developed partial and secondary generalized seizures during IFN-α therapy while displaying a focal disruption of her blood-brain barrier (BBB) corresponding with pathological electroencephalography (EEG). To test our hypothesis that IFN-α induces seizure activity, we exposed rat somatosensory cortices to clinically relevant concentrations of IFN-α in the acute in-vitro slice preparation or in-vivo. While acute exposure did not induce epileptic activity, recordings from slices exposed to IFN-α in-vivo one week prior to recordings revealed pronounced epileptiform activity in > 80% of the slices. We propose that cortical exposure to IFN-α leads to the generation of an epileptic cortex, which explains the weeks of latency in patients from initial treatment to seizures, and stressing the importance of identifying possible BBB disruption among high-risk patients administered peripherally acting drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akeson P, Larsson EM, Kristoffersen DT, Jonsson E, Holtas S (1995) Brain metastases—comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 36:300–306
Ameen M, Russell-Jones R (1999) Seizures associated with interferon-alpha treatment of cutaneous malignancies. Br J Dermatol 141:386–387
Born J, Spath-Schwalbe E, Pietrowsky R, Porzsolt F, Fehm HL (1989) Neurophysiological effects of recombinant interferon-gamma and -alpha in man. Clin Physiol Biochem 7:119–127
Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA (1985) Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am J Med 78:73–78
Cervos-Navarro J, Lafuente JV (1991) Traumatic brain injuries: structural changes. J Neurol Sci 103:3–14
Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA (1994) Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 38:547–557
Gijtenbeek JM, Van Den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246:339–346
Gordon SC (2001) Treatment of viral hepatitis-2001. Ann Med 33:385–390
Gutnick MJ, Connors BW, Prince DA (1982) Mechanisms of neocortical epileptogenesis in-vitro. J Neurophysiol 48:1321–1335
Hampel H, Kotter HU, Padberg F, Korschenhausen DA, Moller HJ (1999) Oligoclonal bands and blood–cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alzheimer Dis Assoc Disord 13:9–19
Janssen HL, Berk L, Vermeulen M, Schalm SW (1990) Seizures associated with low-dose alpha-interferon. Lancet 336:1580
Korn A, Golan H, Melamed I, Pascual-Marqui R, Friedman A (2004) Focal cortical dysfunction and blood-brain barrier disruption in patients with post concussion syndrome. J Clin Neurophysiol (in press)
Pascual-Marqui RD (2002) Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details. Methods Find Exp Clin Pharmacol 24(Suppl D):5–12
Pavlovsky L, Browne RO, Friedman A (2003) Pyridostigmine enhances glutamatergic transmission in hippocampal CA1 neurons. Exp Neurol 179:181–187
Renault PF, Hoofnagle JH (1989) Side effects of alpha interferon. Semin Liver Dis 9:273–277
Renault PF, Hoofnagle JH, ParkY, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA (1987) Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147:1577–1580
Reyes-Vazquez C, Prieto-Gomez B, Georgiades JA, Dafny N (1984) Alpha and gamma interferons’ effects on cortical and hippocampal neurons: microiontophoretic application and single cell recording. Int J Neurosci 25:113–121
Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46:1626–1632
Seiffert E, Dreier P, Ivens S, Beckmann I, Tomkins O, Heinemann U, Friesman A (2004) Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci (in press)
Shakil, AO, Di Bisceglie AM, Hoofnagle JH (1996) Seizures during alpha interferon therapy. J Hepatol 24:48–51
Stein RB, Hanauer SB (2000) Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 23:429–448
Tomkins O, Kaufer D, Korn A, Shelef I, Golan H, Reichenthal E, Soreq H, Friedman A (2001) Frequent bloodbrain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 21:675–691
Volkow ND, Rosen B, Farde L (1997) Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc Natl Acad Sci USA 94:2787–2788
Wiranowska M, Prockop LD, Naidu AK, Saporta S, Kori S, and Kulkarni AP (1994) Interferon entry through the blood-brain barrier in glioma and its effect on lipoxygenase activity. Anticancer Res 14:1121–1126
Woynarowski M, Socha J (1997) Seizures in children during interferon alpha therapy. J Hepatol 26:956–957
Author information
Authors and Affiliations
Corresponding author
Additional information
* Dr. Pavlovsky and Seiffert contributed equally
Rights and permissions
About this article
Cite this article
Pavlovsky*, L., Seiffert*, E., Heinemann, U. et al. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol 252, 42–46 (2005). https://doi.org/10.1007/s00415-005-0596-3
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0596-3